Research and Markets: Acute renal failure (ARF) pipeline review (H2-2011) - therapeutic developments, key players, new products, news, and more...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5a524b/acute_renal_failur) has announced the addition of Global Markets Direct's new report "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011" to their extensive offering of medical market research publications.

“Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011”

Global Markets Direct's Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011 provides an overview of the acute renal failure (ARF) therapeutic pipeline.

This report provides information on the therapeutic development for acute renal failure (ARF) (acute kidney injury), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in therapeutic development for ARF.

Global Markets Direct's latest report is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites, and industry-specific third party sources - all compiled by the Global Markets Direct team.

Scope:

• A snapshot of the global therapeutic scenario for Acute Renal Failure (ARF) (Acute Kidney Injury).
• A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Companies Mentioned:

• Quark Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• BioLineRx, Ltd.
• FibroGen, Inc.
• LEO Pharma A/S
• Hadasit Medical Research Services & Development Ltd
• NicOx SA
• Theratechnologies Inc.
• Torrent Pharmaceuticals Limited
• Am-Pharma B.V.
• Indus Biotech Private Limited
• Angion Biomedica Corp.
• Thrasos, Inc.
• CorMedix, Inc.
• Exponential Biotherapies, Inc.
• Action Pharma A/S
• Kringle Pharma, Inc.
• Nephrx Corporation

For more information visit http://www.researchandmarkets.com/research/5a524b/acute_renal_failur